FDA Inspection 1237197 — SciAnda (Changshu) Pharmaceuticals, Ltd.
The FDA completed an inspection of SciAnda (Changshu) Pharmaceuticals, Ltd. on Mar 29, 2024 in Suzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 29, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Suzhou (China)